Patents by Inventor LAURIE DUMOUTIER

LAURIE DUMOUTIER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for producing antibody using “naked” expression vector expressing type II transmembrane fusion protein
    Patent number: 10138289
    Abstract: Methods are disclosed for generating antibodies and an expression vector used to express protein(s) which provoke the antibody response. The expression vector may be useful in generating an antibody directed to an antigen, comprising a gene in operable linkage with a promoter, which gene encodes upon expressing a fusion protein comprising (i) CD134L, a fragment, homologous or orthologues protein thereof as N-terminal moiety of the fusion protein; and (ii) all or part of an antigenic protein as C-terminal moiety of the fusion protein. To generate the antibodies, the vector is injected into a subject animal, which produces a fusion protein, against which antibodies are generated.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: November 27, 2018
    Assignee: Delphi Genetics S.A.
    Inventors: Jean-Christophe Renauld, Muriel Lemaire, Laurie Dumoutier, Yannick Nizet, Alain Vanderplasschen, Laurent Gillet, Sophie Scohy, Cédric Szpirer
  • METHOD FOR PRODUCING ANTIBODY USING "NAKED" EXPRESSION VECTOR EXPRESSING TYPE II TRANSMEMBRANE FUSION PROTEIN
    Publication number: 20160122413
    Abstract: Methods are disclosed for generating antibodies and an expression vector used to express protein(s) which provoke the antibody response. The expression vector may be useful in generating an antibody directed to an antigen, comprising a gene in operable linkage with a promoter, which gene encodes upon expressing a fusion protein comprising (i) CD134L, a fragment, homologous or orthologues protein thereof as N-terminal moiety of the fusion protein; and (ii) all or part of an antigenic protein as C-terminal moiety of the fusion protein. To generate the antibodies, the vector is injected into a subject animal, which produces a fusion protein, against which antibodies are generated.
    Type: Application
    Filed: January 5, 2016
    Publication date: May 5, 2016
    Inventors: JEAN-CHRISTOPHE RENAULD, MURIEL LEMAIRE, LAURIE DUMOUTIER, YANNICK NIZET, ALAIN VANDERPLASSCHEN, LAURENT GILLET
  • Method for producing antibody using “naked” expression vector expressing type II transmembrane fusion protein
    Patent number: 9234042
    Abstract: Methods are disclosed for generating antibodies and an expression vector used to express protein(s) which provoke the antibody response. The expression vector may be useful in generating an antibody directed to an antigen, comprising a gene in operable linkage with a promoter, which gene encodes upon expressing a fusion protein comprising (i) CD134L, a fragment or homologous protein thereof as N-terminal moiety of the fusion protein; and (ii) all or part of an antigenic protein as C-terminal moiety of the fusion protein. To generate the antibodies, the vector is injected into a subject animal, which produces a fusion protein, against which antibodies are generated.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: January 12, 2016
    Assignee: DELPHI GENETICS SA
    Inventors: Jean-Christophe Renauld, Muriel Lemaire, Laurie Dumoutier, Yannick Nizet, Alain Vanderplasschen, Laurent Gillet
  • METHOD FOR PRODUCING ANTIBODY USING "NAKED" EXPRESSION VECTOR EXPRESSING TYPE II TRANSMEMBRANE FUSION PROTEIN
    Publication number: 20120093825
    Abstract: Methods are disclosed for generating antibodies and an expression vector used to express protein(s) which provoke the antibody response. The expression vector may be useful in generating an antibody directed to an antigen, comprising a gene in operable linkage with a promoter, which gene encodes upon expressing a fusion protein comprising (i) CD134L, a fragment or homologous protein thereof as N-terminal moiety of the fusion protein; and (ii) all or part of an antigenic protein as C-terminal moiety of the fusion protein. To generate the antibodies, the vector is injected into a subject animal, which produces a fusion protein, against which antibodies are generated.
    Type: Application
    Filed: October 18, 2011
    Publication date: April 19, 2012
    Applicant: DELPHI GENETICS SA
    Inventors: JEAN-CHRISTOPHE RENAULD, MURIEL LEMAIRE, LAURIE DUMOUTIER, YANNICK NIZET, ALAIN VANDERPLASSCHEN, LAURENT GILLET